drugset / Trial / NCT00684866

Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma

NCT00684866

Phase 2 Completed 31 enrolled Sumitomo Pharma America, Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to compare the safety and tolerability of levalbuterol HFA metered dose inhaler (MDI) versus racemic albuterol HFA MDI in pediatric subjects 4-11 years of age with asthma

Timeline

Start
2003-01
Primary completion
2003-07
Completion
2003-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Levalbuterol Other / unclassified 45 ug Inhaled
Subject racemic albuterol Unknown 90 ug Inhaled

Indications